LYRICA CR (nda209501)- (82.5MG,165MG,330MG)

Generic Name	PREGABALIN	Innovator	UPJOHN
Dosage	82.5MG,165MG,330MG
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2027-May-02	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2020-Oct-11
GAIN Expiry	None	Drug Complexity	No
Indication	LYRICA CR is indicated for the management of:  Neuropathic pain associated with diabetic peripheral neuropathy (DPN)  Postherpetic neuralgia (PHN)

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
11	0	6

Other Developers

Total Other Developers	16

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
82.5MG	**	**	-	-	2
165MG	**	**	-	-	2
330MG	**	**	-	-	2

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	3

Manufacturing Details of LYRICA CR